Positioned for Long-Duration Growth: Danaher’s Emerging Leadership in Blood-Based Alzheimer’s Diagnostics

Danaher, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Kallum Titchmarsh from Morgan Stanley maintained a Buy rating on the stock and has a $270.00 price target.

Kallum Titchmarsh has given his Buy rating due to a combination of factors tied to Danaher’s positioning in emerging Alzheimer’s diagnostics and the long-term potential of blood-based testing. He notes that Alzheimer’s remains a large, underserved market where current diagnostic pathways are costly, capacity constrained, and slow, creating demand for more scalable solutions. Against this backdrop, Danaher is actively innovating in immunoassay platforms and assays, including the launch of its research-use-only BD‑Tau assay, which aligns the company with a shift toward blood-based biomarkers as an entry point into routine clinical workflows.

At the same time, Titchmarsh acknowledges that early real-world data from the first FDA-cleared blood-based Alzheimer’s test reveal meaningful challenges around specificity, false positives, and clinical interpretation, suggesting that adoption will be gradual and that blood tests will initially serve as triage tools rather than outright replacements for PET or CSF. This dynamic underscores that the market is still developing and that ultimate winners will likely be those who can deliver assays with tighter standardization, better lot-to-lot consistency, and improved reliability in everyday clinical settings. Titchmarsh sees Danaher as well placed to compete on these dimensions, and he views the company’s exposure to this growing diagnostic niche as an attractive, long-duration growth driver that supports a positive stance on the stock.

Titchmarsh covers the Healthcare sector, focusing on stocks such as Danaher, Veracyte, and Natera. According to TipRanks, Titchmarsh has an average return of 9.7% and a 50.00% success rate on recommended stocks.

In another report released on January 13, Argus Research also maintained a Buy rating on the stock with a $265.00 price target.